U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. CO14CIP DIV2

SERIAL NO. 09/342,314

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

SEP 2 2 2000

APPLICANT Michael J. Yellin et al.

FILING DATE June 29, 1999 GROUP 1644

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
Ne	5,474,771	12/12/95	Lederman et al. 424		133.1	Nov. 15, 1991
	5,540,926	7/30/96	Aruffo et al.	424	153.1	Sept. 4, 1992
	5,674,492	10/7/97	Armitage et al.	424	144.1	Dec. 21, 1994
5,677,165 10/14/97 de Boe		de Boer et al.	435	240.27	May 28, 1993	
1:3	5,683,693	11/4/97	Noelle et al.	424	144.1	April 25, 1994
	5,747,037	5/5/98	Noelle et al.	424	154.1	June 7, 1995
	5,833,987	11/10/98	Noelle et al.	424	154.1	June 7, 1995
	5,869,049	2/9/99	Noelle et al	424	154.1	April 25, 1994
	5,876,718	3/2/99	Noelle et al.	424	154.1	March 27, 1998
	5,876,950	3/2/99	Siadak et al.	435	7.23	January 26, 1995
	5,902,585	5/11/99	Noelle et al.	424	144.1	August 5, 1997
	5,916,560 6/29/99 Larsen et al. 5,942,229 8/24/99 Noelle et al. 5,945,513 8/31/99 Aruffo et al.		Larsen et al.	424	154.1	March 20, 1997
			Noelle et al.	424	154.1	June 7, 1995
			Aruffo et al.	530	387.3	July 30, 1996
	5,961,974	10/5/99	Armitage et al.	424	154.1	May 24, 1994
	5,962,406	10/5/99	Armitage et al.	514	8	June 7, 1995
	5,981,724	11/9/99	Armitage et al.	536	23.5	June 7, 1995
	5,993,816	11/30/99	Lederman et al.	424	154.1	June 7, 1995
140	6,001,358	12/14/99	Black et al.	424	154.1	November 7, 1995
		ļ				

EXAMINER

Gammet /3/29/01

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. CO14CIP DIV2

SERIAL NO. 09/342,314

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

SEP 2 2 2000

APPLICANT
Michael J. Yellin et al.

FILING DATE June 29, 1999 GROUP 1644

FOREIGN	PATENT DO	CUMENTS			

		FUREIGN P	ATENT DOCUM	ALINI 3	<u> </u>	TRANSI	ATION
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO_
M	WO 93/08207	4/29/93	PCT	C07H	21/00		
	WO 93/09812	5/27/93	PCT	A61K	39/395		
	WO 94/04570	3/3/94	PCT	C07K	15/06		
	WO 95/06481	3/9/95	PCT	A61K	39/395		
	WO 95/06666	3/9/95	PCT	C07K	16/28		
	WO 95/09653	4/13/95	PCT	A61K	39/395	<i></i>	
	WO 96/23071	8/1/96	PCT	C12N	15/13		
	WO 96/28568	9/19/96	PCT	C12P	21/02		
	WO 96/40246	12/19/96	PCT	A61K	39/395		
$-n\omega$	WO 97/17446	5/15/97	PCT	C12N	15/13		
							<u> </u>

EXAMINER

GIMBEL 3/29/01

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. CO14CIP DIV2

SERIAL NO. 09/342,314

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

SEP 2 2 2000

Michael J. Yellin et al.

APPLICANT

FILING DATE GROUP June 29, 1999 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
EXAMINER INITIAL	
No	Alderson, M.R. et al. "CD40 Expression By Human Monocytes: Regulation By Cytokines And Activation Of Monocytes By The Ligand For CD40", <i>J. Exp. Med.</i> 178:669-674 (1993).
(Bajorath J. et al. "Identification of Residues on CD40 and Its Ligand Which Are Critical for the Receptor-Ligand Interaction", <i>Biochemistry</i> 34:1833-1844 (1995).
	Banchereau J. et al. "The CD40 Antigen and its Ligand", Annual Rev. Immunol. 12:881-922 (1994).
	Biancone, L. et al. "Inhibition of the CD40-CD40Ligand Pathway Prevents Murine Membranous Glomerulonephritis", <i>Kidney Intl.</i> 48:458-468 (1995).
	Buhlmann, J.E. et al. "Therapeutic Potential For Blockade of the CD40 Ligand, gp39", <i>J. Clin. Immunol.</i> 16:83-89 (1996).
	Carbone, A. et al. "Expression of Functional CD40 Antigen on Reed-Sternberg Cells and Hodgkin's Disease Cell Lines", <i>Blood</i> 85(3):780-789 (1995).
	Clark, E.A. et al. "Activation of Human B Cells Mediated Through Two Distinct Cell Surface Differentiation Antigens, Bp35 and Bp50", <i>Proc. Natl. Acad. Sci., USA</i> 83:4494-4498 (1986).
	Cleary, A. M. et al. "Opposing Roles of CD95 (Fas/APO-1) and CD40 in the Death and Rescue of Human Low Density Tonsillar B Cells", <i>J. Immunol.</i> 155:3329-3337 (1995).
	Durie, F.H. et al. "The Role of CD40 and its Ligand (gp39) in Peripheral and Central Tolerance and its Contribution to Autoimmune Disease", Res. Immunol. 145:200-205 (1994).
	Durie, F.H. et al. "The Role of CD40 in the Regulation of Humoral and Cell-Mediated Immunity", <i>Immunol. Today</i> 15:406-411 (1994).
	Durie, F.H. et al. "Prevention of Collagen-Induced Arthritis With An Antibody to gp39, the Ligand for CD40", Science 261:1328-1330 (1993).
	Fanslow W. C. et al. "Soluble Forms of CD40 Inhibit Biologic Responses of Human B Cells", <i>J. Immunol.</i> 149:655-660 (1992).
	Freudenthal, P.S. et al. "The Distinct Surface of Human Blood Dendritic Cells, As Observed After An Improved Isolation Method", <i>Proc. Natl. Acad. Sci., USA</i> 87:7698-7702 (1990).
	Galy, A.H.M. et al. "CD40 is Functionally Expressed on Human Thymic Epithelial Cells", <i>J. Immunol.</i> 149:775-782 (1992).
	Gray, D. et al "Memory B Cell Development But Not Germinal Center Formation is Impaired by In Vivo Blockade of CD40-CD40 Ligand Interaction", <i>J. Exp. Med.</i> 180:141-154 (1994).
	Hasbold, J. et al. "Properties of Mouse CD40: Cellular Distribution of CD40 and B Cell Activation by Monoclonal Anti-Mouse CD40 Antibodies", <i>Eur. J. Of Immunol.</i> 24:1835-1842 (1994).
M	Hollenbaugh, D. et al. "Expression of Functional CD40 by Vascular Endothelial Cells", <i>J. Exp. Med.</i> 182:33-40 (1995).

EXAMINER

Gamace 3/raloj

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. CO14CIP DIV2

SERIAL NO. 09/342,314

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

SEP 2 2 2000

APPLICANT Michael J. Yellin et al.

FILING DATE June 29, 1999 GROUP 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER	OTHER DOCOMENTS (Including Author, Title, Date, Fertilient Pages, Etc.)
INITIAL	
\mathcal{U}_{Λ}	Karmann, K. et al. "CD40 on Human Endothelial Cells: Inducibility by Cytokines and Functional Regulation of Adhesion Molecule Expression", <i>Proc. Natl. Acad. Sci., USA</i> 92:4342-4346 (1995).
	Karpusas, M. et al. "2 Å Crystal Structure of an Extracellular Fragment of Human CD40 Ligand", Structure 3(10): 1031-1039 (1995).
	Kuntz, I.D. "Structure-Based Strategies for Drug Design and Discovery", <i>Science</i> 257:1078-1082 (1992).
	Kuwana, M. et al. "T and B Cell Collaboration is Essential for the Autoantibody Response to DNA Topoisomerase I in Systemic Sclerosis", <i>J. Immunol.</i> 155:2703-2714 (1995).
	Laman, J.D. et al. "The Role of GP39 (CD40 Ligand) in EAE and MS", <i>J. Neuroimmunology</i> 54:175 (1994).
	Larsen, C.P. et al. "CD40-gp39 Interactions Play A Critical Role During Allograft Rejection", Transplantation 61:4-9 (1996).
	Law, C-L. et al. "Analysis of Expression and Function of CD40 on Normal and Leukemic Human B Cell Precursors", <i>Leukemia</i> 4(11):732-738 (1990).
	Lederman, S. et al. "The Understanding of Contact-Dependent T-Cell Helper Function in Molecular, Cellular and Physiological Detail", Res. Immunol. 145:215-222 (1994).
	Mohan, C. et al. "Interaction Between CD40 and Its Ligand gp39 in the Development of Murine Lupus Nephritis", <i>J. Immunol.</i> 154:1470-1480 (1995).
	Merck Manual of Diagnosis And Therapy, 16th Ed. "Idiopathic Infiltrative Diseases Of The Lungs", Merck Research Laboratories, Rahway, NJ 718-720 (1992).
	O'Grady, J.T. et al. "CD40 Expression in Hodgkin's Disease", Am. J. Of Pathology 144:(I):2126 (1994).
	Paulie, S. et al. "A p50 Surface Antigen Restricted to Human Urinary Bladder Carcinomas and B Lymphocytes", Cancer Immunol. Immunother. 20:23-28 (1985).
	Potocnik, A.J. et al. "Expression of Activation Antigens on T Cells in Rheumatoid Arthritis Patients", Scand. J. Immunol. 31:213-224 (1990).
	Stüber, E. et al. "Blocking The CD40L-CD40 Interaction In Vivo Specifically Prevents the Priming of T Helper 1 Cells Through The Inhibition of Interleukin 12 Secretion", <i>J. Exp. Med.</i> 183: 693-698 (1996).
	Uckun, F.M. et al. "Temporal Association of CD40 Antigen Expression With Discrete Stages of Human B-Cell Ontogeny and the Efficacy of Anti-CD40 Immunotoxins Against Clonogenic B-Lineage Acute Lymphoblastic Leukemia As Well As B-Lineage Non-Hodgkin's Lymphoma Cells", <i>Blood</i> 76(12):2449-2456 (1990).
1~	Urashima, M. et al. "CD40 Ligand Triggered Interleukin-6 Secretion In Multiple Myeloma", <i>Blood</i> 85:1903-1912 (1995).

EXAMINER

Grund strato1

FORM	PTO	-1449

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. CO14CIP DIV2

SERIAL NO. 09/342,314

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

SEP 2 2 2000

APPLICANT Michael J. Yellin et al.

FILING DATE June 29, 1999 GROUP 1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) **EXAMINER INITIAL** Valent, P. et al. "Further Characterization Of Surface Membrane Structures Expressed On Human Basophils And Mast Cells", Int. Arch. Allergy Appl. Immunol. 91:198-203 (1990). Westendorf, J.J. et al. "Molecular And Biological Role Of CD40 In Multiple Myeloma". Curr. Top. Microbiol. Immunol. 194:63-72 (1995). Westendorf, J.J. et al. "CD40 Expressions In Malignant Plasma Cells", J. Of Immunol. 152:117-128 Yellin, M.J. et al. "FASEB J. (March 10, 1995) 9(4):A774, Abstract No. 4483 - Oral presentation at FASEB Meeting in Atlanta, Georgia" (1995). Yellin, M.J. et al. "Human Fibroblasts and Endothelial Cells Express CD40 and are Activated by CD40L+ Cells," Poster session at 9th International Congress of Immunology meeting in San Francisco, California (Abstract available July 23, 1995). Yellin, M.J. et al. "Ligation Of CD40 On Fibroblasts Induces CD54 (ICAM-1) and CD106 (VCAM-1) Upregulation And IL-6 Production And Proliferation," J. Leukocyte Biology 58:209-216 (1995). Yellin, M.J. et al. "Functional Interactions Of T Cells With Endothelial Cells: The Role Of CD40L-CD40-Mediated Signals," J. Exp. Med. 182:1857-1864 (1995). Yellin M. J. et al. "In situ Characterization of CD40L and CD40 Expression in Glomerulonephritis (GN)", Abstract May 1, 1996: ASBMB/ASIP/AAI Joint Meeting. Yellin M. J. et al. "Function of CD40 Molecules Expressed on Cultured Synovial Membrane Fibroblasts", FASEB J. 9:A774 - Abstract No. 4483 (1995). Young, L.S. et al. "Identification Of A Human Epithelial Cell Surface Protein Sharing An Epitope With The C3d/Epstein-Barr Virus Receptor Molecule Of B Lymphocytes," Int. J. Cancer 43:786-794 (1989).

EXAMINER

Franser 3/2461